WO2008150446A8 - Inhibitors of protein kinases - Google Patents

Inhibitors of protein kinases Download PDF

Info

Publication number
WO2008150446A8
WO2008150446A8 PCT/US2008/006854 US2008006854W WO2008150446A8 WO 2008150446 A8 WO2008150446 A8 WO 2008150446A8 US 2008006854 W US2008006854 W US 2008006854W WO 2008150446 A8 WO2008150446 A8 WO 2008150446A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
protein kinases
provides
implicated
thiazole
Prior art date
Application number
PCT/US2008/006854
Other languages
French (fr)
Other versions
WO2008150446A1 (en
Inventor
Congxin Liang
Marcel Koenig
Yuanjun He
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of WO2008150446A1 publication Critical patent/WO2008150446A1/en
Publication of WO2008150446A8 publication Critical patent/WO2008150446A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides inhibitors of protein kinases, such as an Src kinase, enzymes which has been implicated in processes such as cell migration, proliferation, and survival. The inhibitors include 2,5-disubstituted derivatives of thiazole wherein the substituents are as defined. The invention also provides a method of using the inhibitors in treatment of cancer, and a method of preparation of the inhibitors by a palladium-catalyzed coupling reaction.
PCT/US2008/006854 2007-05-30 2008-05-30 Inhibitors of protein kinases WO2008150446A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94085907P 2007-05-30 2007-05-30
US60/940,859 2007-05-30

Publications (2)

Publication Number Publication Date
WO2008150446A1 WO2008150446A1 (en) 2008-12-11
WO2008150446A8 true WO2008150446A8 (en) 2011-05-19

Family

ID=40094002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006854 WO2008150446A1 (en) 2007-05-30 2008-05-30 Inhibitors of protein kinases

Country Status (2)

Country Link
TW (1) TW200906825A (en)
WO (1) WO2008150446A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CN102161660B (en) * 2010-02-21 2015-05-20 中国医学科学院药物研究所 Preparation method of 2-(6-chloro-2-methylpyrimidinyl-4-amino)-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
CN103172627B (en) * 2011-12-26 2015-11-18 南京优科生物医药有限公司 Heterocyclic pyrimidinium benzene or pyridine benzene-like compounds and application thereof
CN103012395B (en) * 2013-01-04 2015-05-13 南京优科生物医药有限公司 Preparation method of heterocyclic benzene compound
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016065138A1 (en) 2014-10-22 2016-04-28 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
CN106749223B (en) * 2015-11-25 2019-12-20 中国科学院广州生物医药与健康研究院 Tyrosine kinase inhibitor and preparation method and application thereof
AU2017252276A1 (en) * 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
WO2018048953A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
CN106478519B (en) * 2016-10-10 2018-12-11 上海再启生物技术有限公司 A kind of preparation method of 2- methyl -4- amino -6- chlorine pyrimidine
JP7077335B2 (en) * 2016-12-13 2022-05-30 プリンストン ドラッグ ディスカバリー インコーポレイテッド Protein kinase inhibitor
EP3388430A1 (en) 2017-04-10 2018-10-17 Technische Universität München Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. Therapeutic compounds
TWI667236B (en) 2017-06-13 2019-08-01 財團法人國家衛生研究院 Aminothiazole compounds as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302788B6 (en) * 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ?N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolcarboxamide, use thereof and pharmaceutical composition in which it is comprised
AR044519A1 (en) * 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
JP5112297B2 (en) * 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド Quinoline derivatives useful as modulators of ion channels

Also Published As

Publication number Publication date
TW200906825A (en) 2009-02-16
WO2008150446A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2008150446A8 (en) Inhibitors of protein kinases
WO2008115369A3 (en) Inhibitors of focal adhesion kinase
WO2007041358A3 (en) Substituted pyrazole compounds
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2008098104A8 (en) Inhibitors of akt activity
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
TW200801008A (en) Protein kinase inhibitors
WO2007123892A3 (en) Raf inhibitors and their uses
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
EP1945631B8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2006004884A3 (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2007000339A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2008017361A3 (en) 2-(heterocyclylbenzyl)pyridazinone derivatives
WO2005002576A3 (en) Imidazole derivatives and their use as protein kinases inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NO20083918L (en) Dihydridiazepines useful as inhibitors of protein kinases
MY153727A (en) Pyridazinone derivatives
WO2009011850A3 (en) Novel therapeutic compounds
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2005076990A3 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
WO2006134317A8 (en) Oxadiazole derivatives as dgat inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754804

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 08754804

Country of ref document: EP

Kind code of ref document: A1